Pardes Biosciences

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

Pardes Biosciences headquartered in United States, North America, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $3.0B in funding across 24 round(s). With a team of 11-50 employees, Pardes Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Pre Seed Round - Pardes Biosciences, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.